NO954479D0 - Anvendelse av naturprodukter og beslektede syntetiske forbindelser for behandling ac kardiovaskulære sykdommer - Google Patents

Anvendelse av naturprodukter og beslektede syntetiske forbindelser for behandling ac kardiovaskulære sykdommer

Info

Publication number
NO954479D0
NO954479D0 NO954479A NO954479A NO954479D0 NO 954479 D0 NO954479 D0 NO 954479D0 NO 954479 A NO954479 A NO 954479A NO 954479 A NO954479 A NO 954479A NO 954479 D0 NO954479 D0 NO 954479D0
Authority
NO
Norway
Prior art keywords
treatment
cardiovascular diseases
natural products
synthetic compounds
related synthetic
Prior art date
Application number
NO954479A
Other languages
English (en)
Other versions
NO954479L (no
Inventor
Basil Don Roufogalis
Colin Charles Duke
Qian Li
Original Assignee
Univ Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Sydney filed Critical Univ Sydney
Publication of NO954479D0 publication Critical patent/NO954479D0/no
Publication of NO954479L publication Critical patent/NO954479L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • C07C39/16Bis-(hydroxyphenyl) alkanes; Tris-(hydroxyphenyl)alkanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/14Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with at least one hydroxy group on a condensed ring system containing two rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/12Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings
    • C07C39/15Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic with no unsaturation outside the aromatic rings with all hydroxy groups on non-condensed rings, e.g. phenylphenol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO954479A 1993-06-03 1995-11-08 Anvendelse av naturlige produkter og relaterte syntetiske forbindelser til behandling av kardio-vaskulær sykdom NO954479L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPL918193 1993-06-03
PCT/AU1994/000297 WO1994028886A1 (en) 1993-06-03 1994-06-03 Use of natural products and related synthetic compounds for the treatment of cardiovascular disease

Publications (2)

Publication Number Publication Date
NO954479D0 true NO954479D0 (no) 1995-11-08
NO954479L NO954479L (no) 1996-02-02

Family

ID=3776946

Family Applications (1)

Application Number Title Priority Date Filing Date
NO954479A NO954479L (no) 1993-06-03 1995-11-08 Anvendelse av naturlige produkter og relaterte syntetiske forbindelser til behandling av kardio-vaskulær sykdom

Country Status (16)

Country Link
US (2) US5741821A (no)
EP (1) EP0703780A4 (no)
JP (1) JPH09502163A (no)
KR (1) KR960702749A (no)
CN (1) CN1124922A (no)
BG (1) BG100166A (no)
BR (1) BR9406747A (no)
CA (1) CA2164317A1 (no)
CZ (1) CZ318795A3 (no)
FI (1) FI955786A (no)
HU (1) HUT74174A (no)
NO (1) NO954479L (no)
PL (1) PL311810A1 (no)
SI (1) SI9420037A (no)
SK (1) SK147995A3 (no)
WO (1) WO1994028886A1 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6265540B1 (en) 1997-05-19 2001-07-24 The Johns Hopkins University School Of Medicine Tissue specific prodrug
US6504014B1 (en) 1997-05-19 2003-01-07 The John Hopkins University Tissue specific prodrug
US6545131B1 (en) 1997-05-19 2003-04-08 The Johns Hopkins University Tissue specific prodrug
US6538022B1 (en) 1997-09-24 2003-03-25 Orion Corporation Compounds for deactivating phospholamban function on Ca-ATPase (phopholamban inhibitors)
RU2137472C1 (ru) 1998-10-12 1999-09-20 Тихоокеанский институт биоорганической химии Дальневосточного отделения РАН Лекарственный препарат "гистохром" для лечения острого инфаркта миокарда и ишемической болезни сердца
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
EP1171628A2 (en) * 1999-04-15 2002-01-16 Devgen NV Compound screening methods
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
EP1206934A1 (en) * 2000-11-15 2002-05-22 B. Braun Melsungen Ag Blockade of sodium channels by phenol derivatives
KR100704299B1 (ko) * 2005-11-17 2007-04-09 한국생명공학연구원 신규한 퀴놀린계 화합물, 및 지네 추출물 또는 이로부터 분리된 화합물을 포함하는 심장순환계 질환의 예방 및 치료용 조성물
US9024273B2 (en) * 2010-04-20 2015-05-05 Varian Semiconductor Equipment Associates, Inc. Method to generate molecular ions from ions with a smaller atomic mass

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2321620A (en) * 1940-10-10 1943-06-15 Du Pont Phenolic compounds
DE3527862A1 (de) * 1985-08-02 1987-02-05 Bayer Ag Verfahren zur herstellung von bis-hydroxyphenyl-n-alkanen, neue bis-hydroxyphenyl-n-alkane und neue alkandione

Also Published As

Publication number Publication date
CN1124922A (zh) 1996-06-19
BG100166A (en) 1996-11-29
EP0703780A1 (en) 1996-04-03
WO1994028886A1 (en) 1994-12-22
JPH09502163A (ja) 1997-03-04
FI955786A0 (fi) 1995-12-01
FI955786A (fi) 1996-01-29
HU9503441D0 (en) 1996-01-29
HUT74174A (en) 1996-11-28
SI9420037A (en) 1996-08-31
NO954479L (no) 1996-02-02
CZ318795A3 (en) 1996-06-12
US5741821A (en) 1998-04-21
BR9406747A (pt) 1996-04-02
PL311810A1 (en) 1996-03-18
SK147995A3 (en) 1997-04-09
EP0703780A4 (en) 1998-01-07
KR960702749A (ko) 1996-05-23
US5859067A (en) 1999-01-12
CA2164317A1 (en) 1994-12-22

Similar Documents

Publication Publication Date Title
NO962179L (no) Fremgangsmåte for fremstilling av metallocen og anvendelse derav
FI964874A (fi) Vihannesten käsittely
ATA900296A (de) Verwendung von n-glyoxylprolylesterverbindungen in arzneimitteln
NO944164D0 (no) Fremgangsmåte for fremstilling og anvendelse av en HCl-adsorbent
NO180145C (no) Tannbörste og tildannelse av samme
NO971015L (no) Forbindelser og metoder for behandling av cancer
DE69128316D1 (de) Deodorant und dieses enthaltendes Produkt
FI942993A (fi) Organoaluminoksituote ja sen käyttö
DE69233115D1 (de) Weitere therapeutische Verwendungen von L-Methionine und Zusammensetzungen
NO954479D0 (no) Anvendelse av naturprodukter og beslektede syntetiske forbindelser for behandling ac kardiovaskulære sykdommer
NO965563D0 (no) Behandling og profylakse av osteoporese
NO971900D0 (no) Blandinger og behandling av multippel sklerose
NO941163D0 (no) Behandling av kjött
NO172838C (no) Fremgangsmaate og anlegg for behandling av avfallsprodukter
NO931445D0 (no) Overflatebehandling og fremgangsmaate for tilvirkning av disse
NO940027D0 (no) Fremgangsmaate for fremstilling av derivater av _fenylisoserin og derivatenes anvendelse
NO952820D0 (no) Behandling av avfallspetroleum
NO961226D0 (no) Blandinger for forebyggelse og behandling av viralinduserte tumorer
KR940021607U (ko) 관상어용장치 및 그 콘센트
DE69414159D1 (de) Haferfraktionierungsverfahren und Produkt daraus
NO307740B1 (no) Fremgangsmõte for fremstilling av katalysatorer og anvendelse av denne
FI925144A (fi) Anvaendning av inhibitorer foer faergutvecklingen i kromogena bestaemningar
NO20001758D0 (no) Fremgangsmåter og blandinger for behandling av leddgikt
NO952568D0 (no) Behandling av cellulosemateriale og blandinger for anvendelse for dette
NO973193D0 (no) Kollagen-baserte metoder og formuleringer for behandling av immune system-medierte sykdommer